Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults.
Taparra K, Kekumano K, Benavente R, Roberto L, Gimmen M, Shontell R, Cakobau H, Deo N, Kinslow CJ, Betof Warner A, Deville C, Shing JZ, Vo JB, Patel MI, Pollom E. Taparra K, et al. Among authors: betof warner a. JAMA Netw Open. 2024 Aug 1;7(8):e2430975. doi: 10.1001/jamanetworkopen.2024.30975. JAMA Netw Open. 2024. PMID: 39212989 Free PMC article.
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA. Smithy JW, et al. Among authors: betof warner a. Clin Cancer Res. 2024 Aug 15;30(16):3407-3415. doi: 10.1158/1078-0432.CCR-23-3643. Clin Cancer Res. 2024. PMID: 38767650 Clinical Trial.
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Chen ST, et al. Among authors: betof warner a. J Immunother Cancer. 2024 Apr 10;12(4):e007675. doi: 10.1136/jitc-2023-007675. J Immunother Cancer. 2024. PMID: 38599660 Free PMC article.
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhen R, Weinberg AD, Spencer CN, Ng D, He XY, Albrengues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T. Hirschhorn D, et al. Among authors: betof warner a. Cell. 2023 Mar 30;186(7):1432-1447.e17. doi: 10.1016/j.cell.2023.03.007. Cell. 2023. PMID: 37001503 Free PMC article.
33 results